Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Forthuber Stephen M
   2. Issuer Name and Ticker or Trading Symbol
RADIOLOGIX INC [RGX] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Senior V.P., Field Operations
(Last)
(First)
(Middle)
C/O RADIOLOGIX, INC. 3600 JP MORGAN, CHASE TOWER 2200 ROSS AVENUE		 3. Date of Earliest Transaction (Month/Day/Year)
11/15/2006
(Street)

DALLAS, TX 75201		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $ 4.59 11/15/2006   D     20,250   (1)   (6) Common Stock, par value $.0001 20,250 (6) 0 D  
Stock Option $ 6.06 11/15/2006   D     10,000   (2)   (6) Common Stock, par value $.0001 10,000 (6) 0 D  
Stock Option $ 3.65 11/15/2006   D     10,000   (3)   (7) Common Stock, par value $.0001 10,000 (7) 0 D  
Stock Option $ 6.2 11/15/2006   D     35,000   (1)   (6) Common Stock, par value $.0001 35,000 (6) 0 D  
Stock Option $ 2.6 11/15/2006   D     20,000   (1)   (8) Common Stock, par value $.0001 20,000 (8) 0 D  
Stock Option $ 4.34 11/15/2006   D     45,000   (4)   (9) Common Stock, par value $.0001 45,000 (9) 0 D  
Stock Option $ 1.7 11/15/2006   D     60,000   (5)   (10) Common Stock, par value $.0001 60,000 (10) 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Forthuber Stephen M
C/O RADIOLOGIX, INC. 3600 JP MORGAN
CHASE TOWER 2200 ROSS AVENUE
DALLAS, TX 75201		       Senior V.P., Field Operations  

Signatures

 /s/ Stephen M. Forthuber   11/17/2006
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This option becomes exercisable for 1/60th of the option shares each month for 60 months.
(2) This option became exercisable for 1/6th of the option shares on the grant date and for 1/60th of the option shares each month for 50 months.
(3) This option became exercisable for 1/10th on the grant date and for 1/60th of the option shares each month for 54 months
(4) This option becomes exercisable as to 1/5th of the option shares each year for five years beginning one year after the grant date
(5) The option becomes exercisable for 12,000 shares of the grant total on the first anniversary of the grant date. As to the remaining 48,000 shares, the option vests in equal successive monthly installments of 1,000 shares for 48 months following the first anniversary of the grant date.
(6) Immediately prior to the effective time of the merger, pursuant to the Merger Agreement, these options were accelerated, vested, or otherwise awarded and subsequently cancelled without any exchange of Radiologix Common Stock for Primedex Common Stock or cash payment.
(7) Immediately prior to the effective time of the merger, pursuant to Agreement and Plan of Merger, dated as of July 6, 2006 (the "Merger Agreement"), by and among Radiologix, Inc. ("Radiologix") and Primedex Health Systems, Inc. ("Primedex"), these options were accelerated, vested, or otherwise awarded and subsequently exchanged for a cash payment of $7,800, or $0.78 per share.
(8) Immediately prior to the effective time of the merger, pursuant to the Merger Agreement, these options were accelerated, vested, or otherwise awarded and subsequently exchanged for a cash payment of $36,600, or $1.83 per share.
(9) Immediately prior to the effective time of the merger, pursuant to the Merger Agreement, these options were accelerated, vested, or otherwise awarded and subsequently exchanged for a cash payment of $4,050, or $0.09 per share.
(10) Immediately prior to the effective time of the merger, pursuant to the Merger Agreement, these options were accelerated, vested, or otherwise awarded and subsequently exchanged for a cash payment of $163,800, or $2.73 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.